Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
C$0.24
+4.4%
C$0.23
C$0.10
C$0.35
C$33.38M2.3839,902 shs34,668 shs
NewMarket Co. stock logo
NEU
NewMarket
$586.60
-0.3%
$615.47
$362.16
$650.00
$5.64B0.4536,637 shs37,321 shs
Pfenex Inc. stock logo
PFNX
Pfenex
$12.75
$0.00
$5.26
$14.00
$437.29MN/A503,865 shsN/A
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
+9.30%+4.44%-14.55%+30.56%-6.00%
NewMarket Co. stock logo
NEU
NewMarket
-0.32%-0.43%-6.27%+1.45%+58.19%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/AN/AN/AN/AN/AN/AN/AN/A
NewMarket Co. stock logo
NEU
NewMarket
1.3594 of 5 stars
0.03.01.70.02.33.31.3
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/AN/AN/AN/A
NewMarket Co. stock logo
NEU
NewMarket
N/AN/AN/AN/A
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
C$324.55K102.84C$0.01 per share39.00C$0.02 per share11.75
NewMarket Co. stock logo
NEU
NewMarket
$2.70B2.08$48.52 per share12.09$112.31 per share5.22
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
-C$7.21M-C$0.21N/AN/AN/A-169.75%-45.14%6/26/2024 (Estimated)
NewMarket Co. stock logo
NEU
NewMarket
$388.86M$40.4314.51N/A14.41%41.33%16.70%4/24/2024 (Confirmed)
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/A0.00N/AN/AN/AN/AN/A

Latest BU, NEU, and PFNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2024N/A
NewMarket Co. stock logo
NEU
NewMarket
N/AN/AN/AN/AN/AN/A  
2/14/2024Q3 2024
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/A-C$0.02-C$0.02-C$0.02N/AN/A
1/31/2024Q4 2023
NewMarket Co. stock logo
NEU
NewMarket
N/A$8.38+$8.38$8.38N/A$643.35 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/AN/AN/AN/AN/A
NewMarket Co. stock logo
NEU
NewMarket
$10.001.70%+5.21%24.73%2 Years
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/A

Latest BU, NEU, and PFNX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/22/2024
NewMarket Co. stock logo
NEU
NewMarket
Quarterly$2.501.58%3/14/20243/15/20244/1/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
190.99
1.63
1.71
NewMarket Co. stock logo
NEU
NewMarket
0.60
2.85
1.60
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
0.33%
NewMarket Co. stock logo
NEU
NewMarket
61.09%
Pfenex Inc. stock logo
PFNX
Pfenex
N/A

Insider Ownership

CompanyInsider Ownership
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
29.93%
NewMarket Co. stock logo
NEU
NewMarket
20.40%
Pfenex Inc. stock logo
PFNX
Pfenex
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
24142.03 millionN/ANot Optionable
NewMarket Co. stock logo
NEU
NewMarket
2,0009.59 million7.63 millionOptionable
Pfenex Inc. stock logo
PFNX
Pfenex
7134.30 millionN/ANot Optionable

BU, NEU, and PFNX Headlines

SourceHeadline
NKY Medical Holdings Ltd Class A 300109NKY Medical Holdings Ltd Class A 300109
morningstar.com - January 31 at 6:39 PM
Last available seats at PFS West Coast Conference next weekLast available seats at PFS West Coast Conference next week
pharmaphorum.com - May 19 at 6:04 PM
Ligand Pharmaceuticals and Playa Hotels Resorts Exceed Q1 ... - Best StocksLigand Pharmaceuticals and Playa Hotels Resorts Exceed Q1 ... - Best Stocks
news.google.com - May 4 at 7:30 PM
150+ Active Companies working to develop 160+ Pipeline ... - Digital Journal150+ Active Companies working to develop 160+ Pipeline ... - Digital Journal
news.google.com - April 13 at 12:19 AM
Heres Why You Should Add Ligand (LGND) Stock to Your Portfolio - NasdaqHere's Why You Should Add Ligand (LGND) Stock to Your Portfolio - Nasdaq
news.google.com - April 6 at 5:35 PM
LENZ Therapeutics Closes $83.5M Series B - San Diego Business JournalLENZ Therapeutics Closes $83.5M Series B - San Diego Business Journal
news.google.com - March 29 at 1:06 PM
Ranibizumab Biosimilars Report 2023: Therapies and Ranibizumab ... - Digital JournalRanibizumab Biosimilars Report 2023: Therapies and Ranibizumab ... - Digital Journal
news.google.com - March 17 at 10:21 AM
Global Inflammatory Bowel Disease (IBD) Therapeutics Market to ... - GlobeNewswireGlobal Inflammatory Bowel Disease (IBD) Therapeutics Market to ... - GlobeNewswire
news.google.com - March 15 at 8:24 PM
San Diegos Lenz Therapeutics snags $83.5M for once-a-day eye ... - The San Diego Union-TribuneSan Diego's Lenz Therapeutics snags $83.5M for once-a-day eye ... - The San Diego Union-Tribune
news.google.com - March 15 at 8:24 PM
Osteoporosis Treatment research scope: In-depth Growth Analysis ... - Digital JournalOsteoporosis Treatment research scope: In-depth Growth Analysis ... - Digital Journal
news.google.com - March 13 at 7:40 AM
Current and Future Analysis of Osteoporosis Treatment Market With New Business Strategies and Forecast by 2030 - openPRCurrent and Future Analysis of Osteoporosis Treatment Market With New Business Strategies and Forecast by 2030 - openPR
news.google.com - March 1 at 11:39 AM
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results - The Bakersfield CalifornianLigand Reports Fourth Quarter and Full Year 2022 Financial Results - The Bakersfield Californian
news.google.com - February 23 at 5:24 PM
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results - Business WireLigand Reports Fourth Quarter and Full Year 2022 Financial Results - Business Wire
news.google.com - February 22 at 5:46 PM
Biosimilar Growth Hormones Global Market Report 2023 - Yahoo FinanceBiosimilar Growth Hormones Global Market Report 2023 - Yahoo Finance
news.google.com - February 8 at 4:13 PM
Biosimilar Therapeutic Peptides Global Market Report 2023 - Yahoo FinanceBiosimilar Therapeutic Peptides Global Market Report 2023 - Yahoo Finance
news.google.com - February 8 at 4:13 PM
Osteoporosis Treatment Market Set to Witness Explosive Growth By ... - Digital JournalOsteoporosis Treatment Market Set to Witness Explosive Growth By ... - Digital Journal
news.google.com - February 7 at 3:49 AM
Injectable Drug Delivery Market Dynamic Demand, Growth ... - PharmiWeb.comInjectable Drug Delivery Market Dynamic Demand, Growth ... - PharmiWeb.com
news.google.com - January 27 at 9:00 PM
Osteoporosis Treatment Market Research Scope: In-Depth Growth ... - Digital JournalOsteoporosis Treatment Market Research Scope: In-Depth Growth ... - Digital Journal
news.google.com - January 27 at 9:34 AM
Injectable Drug Delivery Market 2023 Segmentation and Regional Analysis by 2032 - openPRInjectable Drug Delivery Market 2023 Segmentation and Regional Analysis by 2032 - openPR
news.google.com - January 6 at 1:28 PM
Abzena Names Matthew Stober CEO - Contract PharmaAbzena Names Matthew Stober CEO - Contract Pharma
news.google.com - January 5 at 2:36 PM
Abzena hires Matthew Stober to lead the company through the next ... - Bio-IT WorldAbzena hires Matthew Stober to lead the company through the next ... - Bio-IT World
news.google.com - January 4 at 5:54 PM
Osteoporosis Treatment Market Will Reflect Significant Growth Prospects during 2022 – 2028 | Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED. - Digital JournalOsteoporosis Treatment Market Will Reflect Significant Growth Prospects during 2022 – 2028 | Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED. - Digital Journal
news.google.com - December 7 at 8:29 AM
Ligand Reports Third Quarter 2022 Financial Results - StreetInsider.comLigand Reports Third Quarter 2022 Financial Results - StreetInsider.com
news.google.com - November 8 at 4:47 AM
Krystal Biotech Stock: A Buy For Growth Potential (NASDAQ:KRYS) - Seeking AlphaKrystal Biotech Stock: A Buy For Growth Potential (NASDAQ:KRYS) - Seeking Alpha
news.google.com - November 6 at 2:43 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Burcon NutraScience logo

Burcon NutraScience

TSE:BU
Burcon NutraScience Corporation, together with its subsidiaries, develops plant proteins and ingredients for use in the food and beverage industries in Canada. The company offers Peazazz and Peazac, a pea protein for use in dairy alternatives, ready-to-drink beverages, dry blended beverages, bars, baked goods, and meat substitute products. It provides Puratein, a canola protein isolate for use in meat alternatives, such as burgers, sausages, and nutrition bars; Supertein, a canola protein that is a light-colored powder for use in non-dairy frozen desserts, egg alternative, plant-based marshmallows and ready-to-mix beverages, whipped toppings, and plant-based bars; and Nutratein, a canola protein comprising a mixture of globulin and albumin proteins for use in meat and egg alternatives, and other plant-based functional foods. In addition, the company offers Nutratein-PS, a blend of Peazazz pea protein and Supertein canola protein; Nutratein-TZ, a blend of Peazac pea protein and Puratein canola protein; and CLARISOY, a soy protein for use in sports nutrition beverages, citrus-based drinks, fruit-flavored beverages, lemonades, powdered beverage mixes, and non-beverage plant-based products. The company was formerly known as Burcon Capital Corp. and changed its name to Burcon NutraScience Corporation in October 1999. The company was incorporated in 1998 and is headquartered in Vancouver, Canada.
NewMarket logo

NewMarket

NYSE:NEU
NewMarket Corporation, through its subsidiaries, primarily engages in the manufacture and sale of petroleum additives. The company offers lubricant additives for use in various vehicle and industrial applications, including engine oils, transmission fluids, off-road powertrain and hydraulic systems, gear oils, hydraulic oils, turbine oils, and other applications where metal-to-metal moving parts are utilized; engine oil additives designed for passenger cars, motorcycles, on and off-road heavy duty commercial equipment, locomotives, and engines in ocean-going vessels; driveline additives designed for products, such as transmission fluids, axle fluids, and off-road powertrain fluids; and industrial additives designed for products for industrial applications consisting of hydraulic fluids, grease, industrial gear fluids, and industrial specialty applications, such as turbine oils. It also provides fuel additives that are used to enhance the oil refining process and the performance of gasoline, diesel, biofuels, and other fuels to industry, government, original equipment manufacturers, and individual customers. In addition, the company engages in the marketing of antiknock compounds, as well as contracted manufacturing and services activities; and owns and manages a real property in Virginia. It operates in North America, Latin America, Asia Pacific, Europe, the Middle East, Africa, and India. NewMarket Corporation was founded in 1887 and is headquartered in Richmond, Virginia.
Pfenex logo

Pfenex

NYSEAMERICAN:PFNX
Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.